Significant variation of immunohistochemical marker expression in paired primary and metastatic clear cell renal cell carcinomas

American Journal of Clinical Pathology

Volumn 140, Issue 3, 2013, Pages 410-418

  Pan, Zenggang ^a,b   Grizzle, William ^b   Hameed, Omar ^b,c,d  

^a UNIVERSITY OF COLORADO   (United States)

^b University of Alabama at Birmingham   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Carbonic anhydrase IX; Immunohistochemistry; Kidney specific cadherin; Metastatic clear cell renal cell carcinoma; Paired box gene 2; Paired box gene 8; RCC antigen; Renal markers

Indexed keywords

CADHERIN; CARBONATE DEHYDRATASE IX; KIDNEY SPECIFIC CADHERIN; TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG;

ARTICLE; CLEAR CELL CARCINOMA; CLEAR CELL KIDNEY CARCINOMA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

CARBONIC ANHYDRASE IX; IMMUNOHISTOCHEMISTRY; KIDNEY-SPECIFIC CADHERIN; METASTATIC CLEAR CELL RENAL CELL CARCINOMA; PAIRED BOX GENE 2; PAIRED BOX GENE 8; RCC ANTIGEN; RENAL MARKERS;

ANTIGENS, NEOPLASM; CADHERINS; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; PAIRED BOX TRANSCRIPTION FACTORS; PAX2 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84882785225     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP8DMPEIMVH6YP     Document Type: Article

References (27)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Sangoi AR, Karamchandani J, Kim J, et al. The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10. Adv Anat Pathol. 2010;17:377-393.
3. Dierick AM, Praet M, Roels H, et al. Vimentin expression of renal cell carcinoma in relation to DNA content and histological grading: a combined light microscopic, immunocytochemical and cytophotometrical analysis. Histopathology. 1991;18:315-322.
4. Daniel L, Lechevallier E, Giorgi R, et al. Pax-2 expression in adult renal tumors. Hum Pathol. 2001;32:282-287.
5. Kuehn A, Paner GP, Skinnider BF, et al. Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications. Am J Surg Pathol. 2007;31:1528-1533.
6. Shen SS, Krishna B, Chirala R, et al. Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms. Mod Pathol. 2005;18:933-940.
7. Sanjmyatav J, Steiner T, Wunderlich H, et al. A specific gene expression signature characterizes metastatic potential in clear cell renal cell carcinoma. J Urol. 2011;186:289-294.
8. Buchner A, Castro M, Hennig A, et al. Downregulation of HNF-1B in renal cell carcinoma is associated with tumor progression and poor prognosis. Urology. 2010;76:507.e6-11.
9. Lim SD, Young AN, Paner GP, et al. Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases. Virchows Arch. 2008;452:49-55.
10. Ohno Y, Izumi M, Kawamura T, et al. Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer. 2009;101:287-294.
11. Schultz L, Chaux A, Albadine R, et al. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol. 2011;35:1549-1556.
12. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastat "Renal Cell Carcinoma Marker." Am J Surg Pathol. 2001;25:1485-1492.
13. Mazal PR, Exner M, Haitel A, et al. Expression of kidneyspecific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma. Hum Pathol. 2005;36:22-28.
14. Ozcan A, Zhai Q, Javed R, et al. PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidneyspecific cadherin. Arch Pathol Lab Med. 2010;134:1121-1129.
15. Hussain SA, Ganesan R, Reynolds G, et al. Hypoxiaregulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer. 2007;96:104-109.
16. Jarvela S, Parkkila S, Bragge H, et al. Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer. 2008;8:1.
17. Kon-no H, Ishii G, Nagai K, et al. Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma. Lung Cancer. 2006;54:409-418.
18. Span PN, Nagtegaal ID, Bussink J. Expression of carbonic anhydrase IX suggests poor response to therapy in rectal cancer. Br J Cancer. 2009;101:372-373.
19. Winum JY, Scozzafava A, Montero JL, et al. Inhibition of carbonic anhydrase IX: a new strategy against cancer. Anticancer Agents Med Chem. 2009;9:693-702.
20. Zatovicova M, Jelenska L, Hulikova A, et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des. 2010;16:3255-3263.
21. Zhai QJ, Ozcan A, Hamilton C, et al. PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2010;18:323-332.
22. Gokden N, Gokden M, Phan DC, et al. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol. 2008;32:1462-1467.
23. Zannini M, Francis-Lang H, Plachov D, et al. Pax-8, a paired domain-containing protein, binds to a sequence overlapping the recognition site of a homeodomain and activates transcription from two thyroid-specific promoters. Mol Cell Biol. 1992;12:4230-4241.
24. Ozcan A, Shen SS, Hamilton C, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011;24:751-764.
25. Gnarra JR, Dressler GR. Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res. 1995;55:4092-4098.
26. Zhang SL, Guo J, Moini B, et al. Angiotensin II stimulates Pax-2 in rat kidney proximal tubular cells: impact on proliferation and apoptosis. Kidney Int. 2004;66:2181-2192.
27. Chen YJ, Campbell HG, Wiles AK, et al. PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma. Cancer Res. 2008;68:5724-5732.